fusion biopsy
Recently Published Documents


TOTAL DOCUMENTS

368
(FIVE YEARS 165)

H-INDEX

22
(FIVE YEARS 4)

Urology ◽  
2022 ◽  
Author(s):  
Emily Roebuck ◽  
Wei Sha ◽  
Caroline Lu ◽  
Caroline Miller ◽  
Earle Burgess ◽  
...  

2021 ◽  
Author(s):  
Kevin Krughoff ◽  
Dylan M. Buller ◽  
Shuo-Chieh Wu ◽  
Roberto Rodriguez ◽  
Amichai Kilchevsky ◽  
...  
Keyword(s):  

Life ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1432
Author(s):  
Caleb Natale ◽  
Christopher R. Koller ◽  
Jacob W. Greenberg ◽  
Joshua Pincus ◽  
Louis S. Krane

The use of multi-parametric magnetic resonance imaging (mpMRI) in conjunction with the Prostate Imaging Reporting and Data System (PI-RADS) is standard practice in the diagnosis, surveillance, and staging of prostate cancer. The risk associated with lesions graded at a PI-RADS score of 3 is ambiguous. Further characterization of the risk associated with PI-RADS 3 lesions would be useful in guiding further work-up and intervention. This study aims to better characterize the utility of PI-RADS 3 and associated risk factors in detecting clinically significant prostate cancer. From a prospectively maintained IRB-approved dataset of all veterans undergoing mpMRI fusion biopsy at the Southeastern Louisiana Veterans Healthcare System, we identified a cohort of 230 PI-RADS 3 lesions from a dataset of 283 consecutive UroNav-guided biopsies in 263 patients from October 2017 to July 2020. Clinically significant prostate cancer (Gleason Grade ≥ 2) was detected in 18 of the biopsied PI-RADS 3 lesions, representing 7.8% of the overall sample. Based on binomial analysis, PSA densities of 0.15 or greater were predictive of clinically significant disease, as was PSA. The location of the lesion within the prostate was not shown to be a statistically significant predictor of prostate cancer overall (p = 0.87), or of clinically significant disease (p = 0.16). The majority of PI-RADS 3 lesions do not represent clinically significant disease; therefore, it is possible to reduce morbidity through biopsy. PSA density is a potential adjunctive factor in deciding which patients with PI-RADS 3 lesions require biopsy. Furthermore, while the risk of prostate cancer for African-American men has been debated in the literature, our findings indicate that race is not predictive of identifying prostate cancer, with comparable Gleason grade distributions on histology between races.


Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5647
Author(s):  
Byung Kwan Park

TRUS is a basic imaging modality when radiologists or urologists perform cognitive fusion or image fusion biopsy. This modality plays the role of the background images to add to an operator’s cognitive function or MRI images. Operators need to know how to make TRUS protocols for lesion detection or targeting. Tumor location, size, and shape on TRUS are different from those on MRI because the scan axis is different. TRUS findings of peripheral or transition tumors are not well known to radiologists and urologists. Moreover, it remains unclear if systematic biopsy is necessary after a tumor is targeted. The purpose of this review is to introduce new TRUS protocols, new imaging features, new biopsy techniques, and to assess the necessity of systematic biopsy for improving biopsy outcomes.


2021 ◽  
Vol 33 ◽  
pp. S230
Author(s):  
H. Ayerra Pérez ◽  
N. Herrera Aranda ◽  
R. Pinto Martín ◽  
P. Arce Cuartango ◽  
J. Etxano Cantera ◽  
...  

2021 ◽  
Author(s):  
Aditya Bhardwaj ◽  
Praful Mathur ◽  
Tejal Singh ◽  
Venkata Suryanarayana ◽  
Yuri Son ◽  
...  

2021 ◽  
Vol 32 ◽  
pp. S109
Author(s):  
E. Checcucci ◽  
S. De Cillis ◽  
F. Piramide ◽  
D. Amparore ◽  
G. Volpi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document